✦ LIBER ✦

Four-Year Follow-Up of Trastuzumab Plus Adjuvant Chemotherapy for Operable Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Joint Analysis of Data From NCCTG N9831 and NSABP B-31

✍ Scribed by Perez, E. A.; Romond, E. H.; Suman, V. J.; Jeong, J.-H.; Davidson, N. E.; Geyer, C. E.; Martino, S.; Mamounas, E. P.; Kaufman, P. A.; Wolmark, N.

Book ID: 115545565
Publisher: American Society of Clinical Oncology
Year: 2011
Tongue: English
Weight: 257 KB
Volume: 29
Category: Article
ISSN: 0732-183X
DOI: 10.1200/jco.2011.35.0868

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

263 ORAL Doxorubicin and cyclophosphamid

263 ORAL Doxorubicin and cyclophosphamide (AC) followed by paclitaxel (T) with or without trastuzumab (H) as adjuvant therapy for patients with HER2-positive operable breast cancer (BC): combined analysis of NSABP B-31 and NCCTG N9831

📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 138 KB

Seven-Year Follow-Up Assessment of Cardi

Seven-Year Follow-Up Assessment of Cardiac Function in NSABP B-31, a Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Paclitaxel (ACP) With ACP Plus Trastuzumab As Adjuvant Therapy for Patients With Node-Positive, Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer

✍ Zibelman, M.; Goldstein, L.J. 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 54 KB